Dusa Gets FDA Warning On Ad For Actinic Keratoses Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
DDMAC cites firm for broadening the indication, minimizing the risks and overstating the effectiveness of its photosensitizing agent Levulan.